Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

U-BIOPRED: evaluation of the value of a public-private partnership to industry.

Riley JH, Erpenbeck VJ, Matthews JG, Holweg CTJ, Compton C, Seibold W, Higenbottam T, Wagers S, Rowe A, Myles D; Industry Representatives of the U-BIOPRED Study Group.

Drug Discov Today. 2018 Sep;23(9):1622-1634. doi: 10.1016/j.drudis.2018.06.015. Epub 2018 Jun 21. Review.

PMID:
29936248
2.

Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.

Worm M, Higenbottam T, Pfaar O, Mösges R, Aberer W, Gunawardena K, Wessiepe D, Lee D, Kramer MF, Skinner M, Lees B, Zielen S.

Allergy. 2018 Sep;73(9):1812-1822. doi: 10.1111/all.13478. Epub 2018 Jun 19.

3.

Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD.

Montuschi P, Santini G, Mores N, Vignoli A, Macagno F, Shoreh R, Tenori L, Zini G, Fuso L, Mondino C, Di Natale C, D'Amico A, Luchinat C, Barnes PJ, Higenbottam T.

Front Pharmacol. 2018 Apr 17;9:258. doi: 10.3389/fphar.2018.00258. eCollection 2018.

4.

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.

Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, Pandis I, Bansal AT, Bel EH, Auffray C, Compton CH, Bisgaard H, Bucchioni E, Caruso M, Chanez P, Dahlén B, Dahlen SE, Dyson K, Frey U, Geiser T, Gerhardsson de Verdier M, Gibeon D, Guo YK, Hashimoto S, Hedlin G, Jeyasingham E, Hekking PP, Higenbottam T, Horváth I, Knox AJ, Krug N, Erpenbeck VJ, Larsson LX, Lazarinis N, Matthews JG, Middelveld R, Montuschi P, Musial J, Myles D, Pahus L, Sandström T, Seibold W, Singer F, Strandberg K, Vestbo J, Vissing N, von Garnier C, Adcock IM, Wagers S, Rowe A, Howarth P, Wagener AH, Djukanovic R, Sterk PJ, Chung KF; U-BIOPRED Study Group.

Eur Respir J. 2015 Nov;46(5):1308-21. doi: 10.1183/13993003.00779-2015. Epub 2015 Sep 10. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

5.

Detection of COPD Exacerbations and compliance with patient-reported daily symptom diaries using a smart phone-based information system [corrected].

Johnston NW, Lambert K, Hussack P, de Verdier MG, Higenbottam T, Lewis J, Newbold P, Jenkins M, Norman GR, Coyle PV, McIvor RA.

Chest. 2013 Aug;144(2):507-514. doi: 10.1378/chest.12-2308. Erratum in: Chest. 2014 Apr;145(4):929.

PMID:
23519329
6.

A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations.

Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, Higenbottam T, Petruzzelli S, Vestbo J.

Eur Respir J. 2013 Jan;41(1):12-7. doi: 10.1183/09031936.00207611. Epub 2012 May 31.

7.

Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.

Nyberg F, Ogiwara A, Harbron CG, Kawakami T, Nagasaka K, Takami S, Wada K, Tu HK, Otsuji M, Kyono Y, Dobashi T, Komatsu Y, Kihara M, Akimoto S, Peers IS, South MC, Higenbottam T, Fukuoka M, Nakata K, Ohe Y, Kudoh S, Clausen IG, Nishimura T, Marko-Varga G, Kato H.

PLoS One. 2011;6(7):e22062. doi: 10.1371/journal.pone.0022062. Epub 2011 Jul 20.

8.

The Christmas season as a risk factor for chronic obstructive pulmonary disease exacerbations.

Johnston NW, McIvor A, Lambert K, Greene JM, Hussack P, Gerhardsson de Verdier M, Higenbottam T, Lewis J, Newbold P, Herath A, Jenkins M.

Can Respir J. 2010 Nov-Dec;17(6):275-81.

9.

Genetic and environmental influence on lung function impairment in Swedish twins.

Hallberg J, Iliadou A, Anderson M, de Verdier MG, Nihlén U, Dahlbäck M, Pedersen NL, Higenbottam T, Svartengren M.

Respir Res. 2010 Jul 6;11:92. doi: 10.1186/1465-9921-11-92.

10.

Foreword: "The Big Three".

Rennard SI, Higenbottam T, Leff AR.

Proc Am Thorac Soc. 2008 Dec 1;5(8):795. doi: 10.1513/pats.200807-061TH. No abstract available.

PMID:
19017731
11.

The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level.

Kamel N, Compton C, Middelveld R, Higenbottam T, Dahlén SE.

Eur Respir J. 2008 May;31(5):924-6. doi: 10.1183/09031936.00033208. No abstract available.

12.

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12.

PMID:
18337594
13.
14.

Exacerbation-free COPD: a goal too far?

Rennard SI, Higenbottam T.

Proc Am Thorac Soc. 2007 Dec;4(8):583-5.

PMID:
18073386
15.

Interaction between smoking and genetic factors in the development of chronic bronchitis.

Hallberg J, Dominicus A, Eriksson UK, Gerhardsson de Verdier M, Pedersen NL, Dahlbäck M, Nihlén U, Higenbottam T, Svartengren M.

Am J Respir Crit Care Med. 2008 Mar 1;177(5):486-90. Epub 2007 Nov 29.

16.

Developments in inhaled immunosuppressive therapy for the prevention of pulmonary graft rejection.

Akamine S, Katayama Y, Higenbottam T, Lock T.

BioDrugs. 1998 Jan;9(1):49-59.

PMID:
18020556
17.

Personalized medicine and proteomics: lessons from non-small cell lung cancer.

Marko-Varga G, Ogiwara A, Nishimura T, Kawamura T, Fujii K, Kawakami T, Kyono Y, Tu HK, Anyoji H, Kanazawa M, Akimoto S, Hirano T, Tsuboi M, Nishio K, Hada S, Jiang H, Fukuoka M, Nakata K, Nishiwaki Y, Kunito H, Peers IS, Harbron CG, South MC, Higenbottam T, Nyberg F, Kudoh S, Kato H.

J Proteome Res. 2007 Aug;6(8):2925-35. Epub 2007 Jul 17.

PMID:
17636986
18.

Conservation of whole body nitric oxide metabolism in human alcoholic liver disease: implications for nitric oxide production.

Demoncheaux EA, Elphick DA, Dürner MB, Higgins GE, Crowther D, Williams EJ, Higenbottam TW, Gleeson D.

Scand J Gastroenterol. 2006 Jul;41(7):820-5.

PMID:
16785195
19.

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

Calverley P, Pauwels Dagger R, Löfdahl CG, Svensson K, Higenbottam T, Carlsson LG, Ståhl E.

Eur Respir J. 2005 Sep;26(3):406-13. Erratum in: Eur Respir J. 2006 Feb;27(2):440.

20.

Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment.

Higenbottam T.

Proc Am Thorac Soc. 2005;2(1):12-9. Review.

PMID:
16113463
21.

[Guidelines on diagnosis and treatment of pulmonary arterial hypertension].

Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G; Grupo de Trabajo sobre el diagnóstico y tratamiento de la Hipertensión Arterial Pulmonar de la Sociedad Europea de Cardiología.

Rev Esp Cardiol. 2005 May;58(5):523-66. Spanish. No abstract available.

22.

Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension.

Demoncheaux EA, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R, Siddons T, Spivey AC, Hall K, Gize AP.

J Vasc Res. 2005 Mar-Apr;42(2):133-6. Epub 2005 Jan 21.

PMID:
15665548
23.

National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.

Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F, Wolf MK, Steinberg MH, Forsythe BH.

Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):775-87.

PMID:
15654720
24.

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J; Task Force.

Eur Heart J. 2004 Dec;25(24):2243-78. No abstract available.

PMID:
15589643
25.

Understanding the mechanisms of drug-associated interstitial lung disease.

Higenbottam T, Kuwano K, Nemery B, Fujita Y.

Br J Cancer. 2004 Aug;91 Suppl 2:S31-7. Review.

26.

Pulmonary hypertension as a result of drug therapy.

Higenbottam T, Laude L, Emery C, Essener M.

Clin Chest Med. 2004 Mar;25(1):123-31. Review.

PMID:
15062604
27.

Determination of trace concentrations of dissolved nitric oxide in a biological buffer.

Demoncheaux EA, Foster PJ, Borland CD, Smith AP, Higenbottam TW, Davies MB.

Analyst. 2003 Oct;128(10):1281-5. Epub 2003 Sep 15.

PMID:
14667166
28.

Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD.

Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, Germann P, Block LH.

Thorax. 2003 Apr;58(4):289-93.

29.

Inhaled iloprost for severe pulmonary hypertension.

Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study Group.

N Engl J Med. 2002 Aug 1;347(5):322-9.

30.

Chronic cough and the cough reflex in common lung diseases.

Higenbottam T.

Pulm Pharmacol Ther. 2002;15(3):241-7.

PMID:
12099771
31.

Monitoring reactive nitrogen species in biological milieu: a difficult journey.

Demoncheaux E, Crowther D, Spivey AC, Higenbottam TW.

Am J Respir Crit Care Med. 2002 Jun 15;165(12):1670-1; author reply 1671. No abstract available.

PMID:
12070069
32.

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.

Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Solèr M.

Am Heart J. 2002 May;143(5):E4.

PMID:
12040360
33.

Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells.

Smith AP, Demoncheaux EA, Higenbottam TW.

Nitric Oxide. 2002 Mar;6(2):153-9.

PMID:
11890739
34.

Circulating nitrite anions are a directly acting vasodilator and are donors for nitric oxide.

Demoncheaux EA, Higenbottam TW, Foster PJ, Borland CD, Smith AP, Marriott HM, Bee D, Akamine S, Davies MB.

Clin Sci (Lond). 2002 Jan;102(1):77-83.

PMID:
11749663
35.

The direct and indirect action of inhaled agents on the lung and its circulation: lessons for clinical science.

Higenbottam T, Siddons T, Demoncheaux E.

Environ Health Perspect. 2001 Aug;109 Suppl 4:559-62. Review.

36.

Effect of nitric oxide inhibition on nasal airway resistance after nasal allergen challenge in allergic rhinitis.

Maniscalco M, Sofia M, Carratù L, Higenbottam T.

Eur J Clin Invest. 2001 May;31(5):462-6.

PMID:
11380599
37.

Assisted discharge for patients with exacerbations of COPD.

Barber CM, Bradshaw LM, Buttery P, Fishwick D, Whyte MK, Higenbottam TW.

Thorax. 2001 May;56(5):417-8. No abstract available.

38.

Trials of inhaled iloprost and other new vasodilating prostaglandins.

Higenbottam T, Siddons T.

Eur Respir J. 2001 Jan;17(1):6-7. No abstract available.

39.

Effects of an NO-synthase inhibitor L-NMMA in the hepatopulmonary syndrome.

Maniscalco M, Sofia M, Higenbottam T.

Respiration. 2001;68(2):226. No abstract available.

PMID:
11287843
40.

Central retinal vein occlusion associated with primary pulmonary hypertension.

Bhan A, Rennie IG, Higenbottam TW.

Retina. 2001;21(1):83-5. No abstract available.

PMID:
11217943
41.

Use of nitric oxide inhalation in COPD.

Higenbottam TW, Asif M, McCormack K, Siddons TE, Demoncheaux EA.

Thorax. 2000 Nov;55(11):978. No abstract available.

42.

Exhaled nitric oxide is reduced in infants with cystic fibrosis.

Elphick HE, Demoncheaux EA, Ritson S, Higenbottam TW, Everard ML.

Thorax. 2001 Feb;56(2):151-2.

43.

Eradication of house dust mite from homes of atopic asthmatic subjects: a double-blind trial.

Htut T, Higenbottam TW, Gill GW, Darwin R, Anderson PB, Syed N.

J Allergy Clin Immunol. 2001 Jan;107(1):55-60.

PMID:
11149991
44.

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.

Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC.

J Med Genet. 2000 Oct;37(10):741-5.

45.

A therapeutic role for chronic inhaled nitric oxide?

Higenbottam T, Siddons T, Demoncheaux E.

Lancet. 2000 Aug 5;356(9228):446-7. No abstract available.

PMID:
10981884
46.

A randomized trial of dehumidification in the control of house dust mite.

Hyndman SJ, Vickers LM, Htut T, Maunder JW, Peock A, Higenbottam TW.

Clin Exp Allergy. 2000 Aug;30(8):1172-80.

PMID:
10931126
47.

The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance.

Higenbottam T, Marriott H, Cremona G, Laude E, Bee D.

Chest. 1999 Oct;116(4):921-30.

PMID:
10531154
48.

Hemodynamic effects of basal and stimulated release of endogenous nitric oxide in isolated human lungs.

Cremona G, Higenbottam TW, Bower EA, Wood AM, Stewart S.

Circulation. 1999 Sep 21;100(12):1316-21.

PMID:
10491377
49.

Treatments for severe pulmonary hypertension.

Higenbottam T, Stenmark K, Simonneau G.

Lancet. 1999 Jan 30;353(9150):338-40. Review. No abstract available.

PMID:
9950432
50.

Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas.

Katayama Y, Higenbottam TW, Cremona G, Akamine S, Demoncheaux EA, Smith AP, Siddons TE.

Circulation. 1998 Dec 1;98(22):2429-32.

PMID:
9832488

Supplemental Content

Loading ...
Support Center